2015 was a good year in terms of new drugs approvals by the FDA. The total for 2015 stood at 45. It was the highest number. The previous record was in 1996 with 43 new products approved by the FDA ...Samsung BioLogics expects to become the world’s largest biologics CMO
With a total investment of 650 million euros, the third plant will be a world-leading facility both in terms of capacity (180,000 liters) and production efficiency. The plant is expected to be completed by 2017 and begin operation in the fourth quarter of 2018 after validation...JV between Bayer and CRISPR Therapeutics
In December, Bayer announced that it will invest 300 million dollars over the next five years in R&D on therapeutics to cure blood disorders, blindness and congenital heart disease. Bayer will create a joint-venture with CRISPR Therapeutics, which will bring its CRISPR- Cas9 gene-editing technology and intellectual property...BIO-Europe Spring® 2016
The tenth annual BIO-Europe Spring® international partnering conference will be held April 4–6, 2016, at the Kistamässan Convention Center in Stockholm. The event is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe®, and last year welcomed more than 2,300 participants representing over 1,350 companies from 53 countries vying for an estimated 2,600 licensing opportunities. Close to 12,500 one-to-one meetings took place at that event between companies across the life science value chain, from large biotech and pharma companies to financiers and innovative startups. ...2020 R&D forecasts
AbbVie plans to deliver double-digit earnings growth through 2020, with annual sales forecast to reach approximately 37 billion dollars by the end of the period. The company remains on track to launch more than 20 new products or indications by 2020, including seven approvals. Among these include expanded approvals of Imbruvica for first-line chronic lymphocytic leukaemia and Humira in hidradenitis suppurativa and uveitis, as well as Viekira Pak for the treatment of genotype 1 hepatitis C in Japan. ...The top pharma deals
2015 ended with a new record for Mergers and Acquisitions. At the end of December global transaction volumes had exceeded $4,700 billion, a 42% increase over the previous year. The health sector leads Mergers and Acquisitions, ahead of the High Tech sector, with a volume greater than $500 billion. In the pharmaceutical industry, mega deals were announced in 2015: the acquisition of Hospira by Pfizer ($17 billion), the acquisition of Pharmacyclics by AbbVie ($21 billion), the acquisition of the generic division of Allergan by Teva ($40 billion) and during the last quarter the exchange of assets between Sanofi and Boehringer Ingelheim ($20 billion dollars) and the acquisition of Allergan by Pfizer ($160 billion dollars)...Investments go on
Despite difficulties to enter the Chinese market or to develop sales under the Chinese rules, western companies haven’t slowed their investments. In December, AstraZeneca unveiled various initiatives to accelerate the delivery of innovative biologics and targeted medicines to patients in China. This plan will include an expanded alliance with WuXi AppTec. ...
PHARMAnetwork magazine audience is comprised of the top executives across the pharmaceutical value chain, from R&D, to production, to finance - we have the top decision makers in the industry.
More than 90% of our subscribers hold key positions in the industry.
Learn more about who reads PHARMAnetwork magazine and how your brand can connect with that audience mail to: firstname.lastname@example.org
1 Rue de Lille
Tel: 33 (0)1 42 97 97 97
Fax: 33 (0)1 42 97 97 12